Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXEL-LTE-1: Long-Term Extension Study of Exelixis-Sponsored Treatments
NCT07620574Phase 3Enrolling by invitation
- Sponsor
- Exelixis, Inc.
- Start
- Jul 2026
- Primary completion
- May 2030
- Countries
- 1
01
Overview
A Phase 3 trial of cabozantinib, zanzalintinib in renal cell carcinoma (RCC), Pancreatic neuroendocrine tumor (PanNET), extra-pancreatic neuroendocrine tumor, hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), sponsored by Exelixis, Inc.. Started Jul 2026; status: enrolling by invitation.
02
Drugs
cabozantinibzanzalintinib
03
Conditions
renal cell carcinoma (RCC)Pancreatic neuroendocrine tumor (PanNET)extra-pancreatic neuroendocrine tumorhepatocellular carcinoma (HCC)differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT07620574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620574.